Genmab — December 2015
-
-
-
Janssen update - Daratumumab mono - 70% response. 50% of responders progression-free at 12 months. Dara is Rituxan for MM.
-
Fuldstændigt vildt.
-
Og de røde ører?
-
''Dara is Rituxan for MM'' - Den sammenligning kan vi li'
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind